Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6226 to 6240 of 7680 results

  1. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

  2. Type 2 diabetes: empagliflozin (ESNM35)

    This evidence summary has been replaced by NICE technology appraisal guidance 336.

  3. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

  4. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

  5. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

  6. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

  7. Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

    This evidence summary has been replaced by NICE technology appraisal guidance 486.  

  8. Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)

    This evidence summary was withdrawn in September 2017 as the medicine is no longer available.

  9. Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

    This advice has been updated and replaced by NICE guideline NG221.

  10. Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

    This evidence summary has been updated and replaced by NICE guideline 115.

  11. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

  12. Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

    This evidence summary has been updated and replaced by NICE guideline NG39.

  13. Nocturia and nocturnal polyuria in men with lower urinary tract symptoms: oral desmopressin (ESUOM10)

    This evidence summary has been withdrawn because a product containing oral desmopressin with a marketing authorisation for treating nocturia and nocturnal polyuria in men with lower urinary tract symptom is now available in the UK.

  14. Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

    This evidence summary has been updated and replaced by NICE guideline NG207.